Pretreatment Neutrophil to Lymphocyte Ratio (NLR)‎ Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide

الملخص EN

Introduction.

Nearly 80% of advanced prostate cancer patients respond to initial androgen deprivation therapy (ADT).

However, ADT does not prevent the progression of prostate cancer over the long term, and the disease eventually progresses to castration-resistant prostate cancer (CRPC).

Prior to the development of enzalutamide (ENZ) and abiraterone acetate, docetaxel was the only established treatment with life-prolongation for CRPC.

ENZ is a second-generation anti-androgen receptor drug that has contributed to improving the prognosis of CRPC.

Several studies have reported factors predicting the efficacy of ENZ; however, there are no confirmed biomarkers.

The neutrophil-to-lymphocyte ratio (NLR) is an easily calculated biomarker that is associated with the prognosis of several solid malignancies.

However, there were few studies investigated NLR for ENZ in patients with mCRPC.

We examined the usefulness of the NLR as a predictive tool for ENZ.

Methods.

We retrospectively examined a total of 106 CRPC patients who were treated with ENZ until September 2016 in Yokohama City University Hospital, Yokohama City University Medical Center, and National Cancer Center Hospital East.

ENZ was routinely started as a dose of 160 mg per day; the dosage was reduced in some patients due to side effects.

Drug holiday for 1-2 weeks or dose reduction to 80-120mg was done and no patients discontinued ENZ treatment due to adverse effects.

ENZ was stopped when cancer progression was detected based on PSA elevation, radiographic findings, and deterioration of the patient’s performance status.

The cut-off NLRs for overall survival (OS) and cancer-specific survival (CSS) were determined based on the receiver-operator curves.

Kaplan-Meier curves were used to analyze the factors associated with OS or CSS and a log-rank test was performed.

A multivariate analysis was also performed to analyze the factors associated with the prognosis.

Results.

We retrospectively reviewed 106 consecutive CRPC patients who were both treated with ENZ and were able to be counted before ENZ NLR.

Cut-off point was 2.14 for both OS and CSS by receiver operator characteristic curve.

The patients were then divided into the higher NLR group (≥2.14) and lower NLR group (<2.14).

Multivariate analysis showed that NLR and predocetaxel chemotherapy were independent risk factors for both overall and cancer-specific survival.

Conclusions.

The NLR might be a useful biomarker for predicting the prognosis of mCRPC patients who are treated with ENZ.